Erytech Financial Statements From 2010 to 2024
| ERYPDelisted Stock | USD 0.78 0.04 4.88% |
Check Erytech Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Erytech main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Erytech financial statements analysis is a perfect complement when working with Erytech Pharma Valuation or Volatility modules.
Erytech |
Erytech Pharma SA Company Operating Margin Analysis
Erytech Pharma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Erytech Pharma Operating Margin | (4.08) % |
Most of Erytech Pharma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Erytech Pharma SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Erytech Pharma SA has an Operating Margin of -4.0841%. This is 88.36% lower than that of the Biotechnology sector and 96.36% lower than that of the Health Care industry. The operating margin for all United States stocks is 25.88% lower than that of the firm.
Erytech Pharma SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Erytech Pharma's current stock value. Our valuation model uses many indicators to compare Erytech Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Erytech Pharma competition to find correlations between indicators driving Erytech Pharma's intrinsic value. More Info.Erytech Pharma SA is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Erytech Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Erytech Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Erytech Pharma's earnings, one of the primary drivers of an investment's value.About Erytech Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Erytech Pharma income statement, its balance sheet, and the statement of cash flows. Erytech Pharma investors use historical funamental indicators, such as Erytech Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Erytech Pharma investors may use each financial statement separately, they are all related. The changes in Erytech Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Erytech Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Erytech Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Erytech Pharma. Please read more on our technical analysis and fundamental analysis pages.
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. The company was incorporated in 2004 and is headquartered in Lyon, France. Erytech Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |